Innovation in AD Diagnosis: Labcorp pTau217 Marker (2024)

484390

Phosphorylated Tau 217 (pTau-217), Plasma

An aid in the identification of Alzheimer's disease pathology by detecting the presence or absence of pTau-217, which has been shown in the literature to be a surrogate of amyloid pathology. Additionally, pTau-217 can be used for monitoring patients on newly approved anti-amyloid therapies

View Test Details

505725

Beta Amyloid 42/40 Ratio, Plasma

Labcorp’s Beta-Amyloid 42/40 Ratio test quantifies the amount of beta-amyloid 42 and 40 proteins in a plasma patient sample and computes the ratio of those proteins, providing an indication of amyloid pathology for Alzheimer’s disease

View Test Details

484440

Glial Fibrillary Acidic Protein (GFAP)

GFAP is a protein expressed mostly in astrocytes in the brain. In conjunction with markers of amyloid pathology, GFAP has been shown to be a predictor of Alzheimer's disease

View Test Details

140555

Neurofilament Light Chain, Plasma

NfL, in the context of Alzheimer’s disease, provides an indication of disease severity by measuring the current level of neurodegeneration

View Test Details

483745

Phosphorylated Tau 181 (pTau-181), Plasma

This test detects and quantifies pTau-181 proteins in plasma, which has been demonstrated to be predictive in differentiating Alzheimer’s from other dementias

View Test Details

484400

ATN Profile

This profile is used to assist in determining the presence or absence of key biological changes that are consistent with Alzheimer's disease pathology

Labcorp’s Alzheimer’s Disease Evaluation Profile measures β‑Amyloid (1‑42) (Abeta42), total Tau (tTau) and Phospho‑Tau (181P) (pTau181) protein concentrations in cerebrospinal fluid (CSF) from adult patients aged 55 years and older being evaluated for Alzheimer's disease (AD) and other causes of cognitive impairment to generate a to generate a tTau/Abeta42 ratio value and a pTau181/Abeta42 ratio value.

Learn More

Labcorp's Beta-Amyloid 42/40 Ratio test quantifies the amount of beta-amyloid 42 and 40 proteins in a CSF patient sample and computes the ratio of those proteins, providing an indication of disease progression. Studies have shown strong correlation of CSF beta-amyloid levels to PET scan results. This test can be a surrogate to more costly PET scan imaging.

Learn More

This test detects the presence of the Apolipoprotein E (APOE)-4 variant, which is associated with increased risk of late-onset (age >60-65) Alzheimer's disease (AD). Testing may be considered for patients with dementia to supplement information from clinical and other evaluations. APOE has multiple roles, including lipid transport in the blood and the brain. The APOE4 variant increases the risk for late-onset Alzheimer's disease and may contribute to the pathology of the disease through influence on β-amyloid, inflammation, or other processes.

Learn More

AD is a complex and heterogeneous disease, influenced by many genetic and environmental factors. Early onset familial AD (presenting between 25-60) occurs in less than 2% of AD cases. This test analyzes three genes (amyloid protein precursor (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2)) to detect pathogenic variants that cause autosomal dominant early onset Alzheimer's disease. Testing may be considered to confirm a diagnosis of early onset Alzheimer's disease in symptomatic individuals.

Learn More

Genetics can play a significant role in the development of certain neurodegenerative diseases. In some cases, genetic testing may help confirm a diagnosis.

Learn More

Characterized by progressive muscle loss and weakness, our tests can detect the genetic mutations that cause the most common forms.

Learn More

While no single test can diagnose multiple sclerosis, lab tests may help doctors rule out other diseases and confirm a diagnosis.

Learn More

The increasing prevalence of neurodegenerative diseases has fueled the need for advanced research into pharmaceutical solutions and related neuro biomarkers.

Learn More